Andrea Pellagatti
Overview
Explore the profile of Andrea Pellagatti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
103
Citations
4444
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sun T, Singh S, Wang H, Lee J, Dolatshad H, Cheong P, et al.
Br J Haematol
. 2025 Feb;
PMID: 39988885
We sought to identify new candidate drugs for repurposing to myelodysplastic syndromes (MDS). Connectivity map analysis was performed on gene expression signatures generated from bone marrow CD34 cells of splicing...
2.
Pellagatti A, Boultwood J
Adv Biol Regul
. 2024 Oct;
95:101055.
PMID: 39406588
The transcription factor NF-κB plays a critical role in the control of innate and adaptive immunity and inflammation. Several recent studies have demonstrated that the mutation of different splicing factor...
3.
Gerlevik S, Seymen N, Hama S, Mumtaz W, Thompson I, Jalili S, et al.
Elife
. 2024 Sep;
13.
PMID: 39235452
Mutational profiles of myelodysplastic syndromes (MDS) have established that a relatively small number of genetic aberrations, including SF3B1 and SRSF2 spliceosome mutations, lead to specific phenotypes and prognostic subgrouping. We...
4.
Bernard E, Hasserjian R, Greenberg P, Arango Ossa J, Creignou M, Tuechler H, et al.
Blood
. 2024 Jul;
144(15):1617-1632.
PMID: 38958467
Myelodysplastic syndromes (MDS) are clonal hematologic disorders characterized by morphologic abnormalities of myeloid cells and peripheral cytopenias. Although genetic abnormalities underlie the pathogenesis of these disorders and their heterogeneity, current...
5.
Sirenko M, Bernard E, Creignou M, Domenico D, Farina A, Arango Ossa J, et al.
Blood
. 2024 Apr;
144(11):1221-1229.
PMID: 38687605
Mutations in UBA1, which are disease-defining for VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome, have been reported in patients diagnosed with myelodysplastic syndromes (MDS). Here, we define the prevalence...
6.
Bernard E, Tuechler H, Greenberg P, Hasserjian R, Arango Ossa J, Nannya Y, et al.
NEJM Evid
. 2024 Feb;
1(7):EVIDoa2200008.
PMID: 38319256
BACKGROUND: Risk stratification and therapeutic decision-making for myelodysplastic syndromes (MDS) are based on the International Prognostic Scoring System–Revised (IPSS-R), which considers hematologic parameters and cytogenetic abnormalities. Somatic gene mutations are...
7.
Tatwavedi D, Pellagatti A, Boultwood J
Adv Biol Regul
. 2023 Oct;
91:100993.
PMID: 37827894
Acquired myeloid malignancies are a spectrum of clonal disorders known to be caused by sequential acquisition of genetic lesions in hematopoietic stem and progenitor cells, leading to their aberrant self-renewal...
8.
Harris B, Singh D, Verma M, Fahl S, Rhodes M, Sprinkle S, et al.
bioRxiv
. 2023 Jul;
PMID: 37398007
Highlights: RPL22 insufficiency is observed in MDS/AML and is associated with reduced survivalRpl22-deficiency produces an MDS-like syndrome and facilitates leukemogenesisRpl22-deficiency does not impair global protein synthesis by HSCRpl22 controls leukemia...
9.
Mongiorgi S, De Stefano A, Ratti S, Indio V, Astolfi A, Casalin I, et al.
Clin Epigenetics
. 2023 Feb;
15(1):27.
PMID: 36803590
Background: miRNAs are small non-coding RNAs that regulate gene expression and are linked to cancer development and progression. miRNA profiles are currently studied as new prognostic factors or therapeutic perspectives....
10.
Pellagatti A, Boultwood J
Adv Biol Regul
. 2022 Oct;
87:100920.
PMID: 36216757
Mutations of splicing factor genes (including SF3B1, SRSF2, U2AF1 and ZRSR2) occur in more than half of all patients with myelodysplastic syndromes (MDS), a heterogeneous group of myeloid neoplasms. Splicing...